Subsoontorn Lab:Research: Difference between revisions
From OpenWetWare
Jump to navigationJump to search
Line 9: | Line 9: | ||
<font size = "2"> | <font size = "2"> | ||
Our ability to study and utilise microbiota is limited by the lack of tools for precisely perturbing and modulating microbial subpopulations of interest within a heterogenous population. Recently, CRISPR/Cas technology was used for creating antimicrobials with a programmable spectrum of activities.This strategy exploits the fact that CRISPR/Cas system can be designed to break a specific DNA sequence in a genome. In a prokaryotic cell without efficient DNA double-strand break repair, such genomic cleavage often results in cell death. By delivering the designed CRISPR/Cas system to a microbial population one could selectively knockdown a subpopulation whose genomic DNA is targeted. Previous works demonstrated sequence-specific elimination of Escherichia coli and Staphylococcus aureus in mixed populations. Here, we are applying this strategy for targeted | Our ability to study and utilise microbiota is limited by the lack of tools for precisely perturbing and modulating microbial subpopulations of interest within a heterogenous population. Recently, CRISPR/Cas technology was used for creating antimicrobials with a programmable spectrum of activities.This strategy exploits the fact that CRISPR/Cas system can be designed to break a specific DNA sequence in a genome. In a prokaryotic cell without efficient DNA double-strand break repair, such genomic cleavage often results in cell death. By delivering the designed CRISPR/Cas system to a microbial population one could selectively knockdown a subpopulation whose genomic DNA is targeted. Previous works demonstrated sequence-specific elimination of Escherichia coli and Staphylococcus aureus in mixed populations. Here, we are applying this strategy for targeted elimination of Vibrio harveyi, a pathogenic bacteria in black tiger shrimp and Pacific white shrimp. This project is under collaboration with Dr. Wanilada Rungrassamee (BIOTEC) and Prof. Dr. Jim Haseloff (University of Cambridge, UK) | ||
</font > | </font > |
Revision as of 20:33, 9 May 2017
Current Research
Past Research
|